HSPA5 and prostate cancer: In vitro studies with a recombinant GRP78 antibody (AEP8587) show that this antibody competes with a prostate cancer patient-derived GRP78 autoantibody, decreasing the induction of UPR and tissue factor-procoagulation activity associated with prostate cancer progression [83].